Salubris Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Subsidiary
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.salubrisbio.com
Study of JK06 in Patients with Unresectable Locally Advanced or Metastatic Cancer
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Target Recruit Count
- 155
- Registration Number
- NCT06667960
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇧🇪UZ Ghent, Ghent, Belgium
Study of JK07 in Patients With Chronic Heart Failure
Phase 2
Recruiting
- Conditions
- Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Target Recruit Count
- 282
- Registration Number
- NCT06369298
- Locations
- 🇺🇸
Site 138, Huntsville, Alabama, United States
🇺🇸Site 127, Little Rock, Arkansas, United States
🇺🇸Site 158, Orange, California, United States
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1
Active, not recruiting
- Conditions
- Metastatic CancerSmall-cell Lung CancerUrothelial CarcinomaPancreatic AdenocarcinomaThyroid CancerTumor, SolidAdvanced Solid TumorNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckLuminal Breast Cancer
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Target Recruit Count
- 263
- Registration Number
- NCT05620134
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪UZA, Edegem, Belgium
🇧🇪UZ Ghent, Ghent, Belgium
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
Phase 1
Withdrawn
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Registration Number
- NCT05322616
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Harvard Medical School/Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
Phase 1
Completed
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Salubris Biotherapeutics Inc
- Target Recruit Count
- 14
- Registration Number
- NCT04210375
- Locations
- 🇺🇸
University of Arizona College of Medicine, Tucson, Arizona, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath